全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。
Access in all areas? A round up of developments in market access and health technology assessment: part 1.
机构信息
MSD Innovation & Development, Zurich, 8058, Switzerland.
Lane Clark & Peacock, London, W1U 1DQ, UK.
出版信息
J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.
Abstract
In this new series reviewing recent developments in market access, we highlight publications investigating health technology assessment (HTA) guidance, review processes and outcomes across the world and discuss how forthcoming changes in the HTA and regulatory environment in the European Union may allow for more consistency in decision making.
摘要
在这个新的系列中，我们回顾了市场准入的最新动态，重点介绍了研究全球范围内卫生技术评估（HTA）指南、审查流程和结果的出版物，并讨论了即将在欧盟的 HTA 和监管环境中发生的变化如何能够使决策更加一致。
相似文献
1
Access in all areas? A round up of developments in market access and health technology assessment: part 1.全覆盖准入政策？市场准入和卫生技术评估发展综述：第 1 部分。
J Comp Eff Res. 2023 Oct;12(10):e230129. doi: 10.57264/cer-2023-0129. Epub 2023 Aug 16.
2
Health technology assessment of medical devices: What is different? An overview of three European projects.医疗设备的卫生技术评估：有何不同？三个欧洲项目概述。
Z Evid Fortbild Qual Gesundhwes. 2015;109(4-5):309-18. doi: 10.1016/j.zefq.2015.06.011. Epub 2015 Jul 26.
3
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 6.我们准备好申请报销了吗？健康技术评估相关真实世界证据的进展综述：第6部分。
J Comp Eff Res. 2022 May;11(7):473-475. doi: 10.2217/cer-2022-0043. Epub 2022 Mar 9.
4
Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union's Regulation on Health Technology Assessment for Vaccines.指导欧盟联合卫生技术评估中疫苗评估的原则：为欧盟疫苗卫生技术评估法规做准备。
Value Health. 2024 Oct;27(10):1318-1327. doi: 10.1016/j.jval.2024.06.011. Epub 2024 Jul 6.
5
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 4.我们准备好申请报销了吗？与卫生技术评估相关的真实世界证据进展综述：第4部分。
J Comp Eff Res. 2022 Jan;11(1):11-12. doi: 10.2217/cer-2021-0243. Epub 2021 Oct 27.
6
European collaboration on health technology assessment: looking backward and forward.欧洲卫生技术评估合作：回顾与展望。
Int J Technol Assess Health Care. 2022 Apr 19;38(1):e34. doi: 10.1017/S026646232200006X.
7
Access in all areas? a round up of developments in market access and health technology assessment: part 4.所有领域都能准入吗？市场准入和卫生技术评估发展情况综述：第 4 部分。
J Comp Eff Res. 2024 Jun;13(6):e240060. doi: 10.57264/cer-2024-0060. Epub 2024 Apr 22.
8
[Policy developments of health technology assessment in the European Union].[欧盟卫生技术评估的政策发展]
Postepy Biochem. 2019 Nov 29;65(4):319-321. doi: 10.18388/pb.2019_285.
9
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 10.我们是否已经准备好进行报销了？关于与健康技术评估相关的真实世界证据的最新进展综述：第 10 部分。
J Comp Eff Res. 2023 Jan;12(1):e220194. doi: 10.2217/cer-2022-0194. Epub 2022 Dec 1.
10
R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 7.我们是否已准备好进行报销？与健康技术评估相关的真实世界证据的最新进展：第 7 部分。
J Comp Eff Res. 2022 Jul;11(10):699-701. doi: 10.2217/cer-2022-0071. Epub 2022 May 4.
引用本文的文献
1
The need to consider market access for pharmaceutical investment decisions: a primer.制药投资决策中考虑市场准入的必要性：入门指南。
J Comp Eff Res. 2025 May;14(5):e250036. doi: 10.57264/cer-2025-0036. Epub 2025 Apr 4.
2
Access in all areas? A roundup of developments in market access and health technology assessment: part 6.全面准入？市场准入与卫生技术评估进展综述：第6部分。
J Comp Eff Res. 2025 Mar;14(3):e240239. doi: 10.57264/cer-2024-0239. Epub 2025 Jan 10.
3
EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?欧盟卫生技术评估联合临床评估：罕见病患者会因此处于劣势吗？
J Comp Eff Res. 2024 Jun;13(6):e240052. doi: 10.57264/cer-2024-0052. Epub 2024 May 2.
4
Access in all areas? a round up of developments in market access and health technology assessment: part 4.所有领域都能准入吗？市场准入和卫生技术评估发展情况综述：第 4 部分。
J Comp Eff Res. 2024 Jun;13(6):e240060. doi: 10.57264/cer-2024-0060. Epub 2024 Apr 22.
本文引用的文献
1
Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study.癌症药物的卫生技术评估在 G7 国家和大洋洲：一项国际、横断面研究。
Lancet Oncol. 2023 Jun;24(6):624-635. doi: 10.1016/S1470-2045(23)00175-4.
2
A review of HTA guidelines on societal and novel value elements.关于 HTA 指南中社会和新颖价值要素的综述。
Int J Technol Assess Health Care. 2023 May 25;39(1):e31. doi: 10.1017/S026646232300017X.
3
Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries.新型抗癌药物在欧洲的报销时间：七个欧洲国家的案例研究。
ESMO Open. 2023 Apr;8(2):101208. doi: 10.1016/j.esmoop.2023.101208. Epub 2023 Apr 6.
4
What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries.是什么推动了 HTA 决策？来自 6 个欧洲国家癌症药物报销决策的证据。
Health Policy. 2019 Feb;123(2):130-139. doi: 10.1016/j.healthpol.2018.11.003. Epub 2018 Nov 20.
5
Defining Elements of Value in Health Care-A Health Economics Approach: An ISPOR Special Task Force Report [3].医疗保健价值的定义要素——一种卫生经济学方法：一份ISPOR特别工作组报告[3]
Value Health. 2018 Feb;21(2):131-139. doi: 10.1016/j.jval.2017.12.007.
Zotero 插件